PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with ...

Fintel reports that on March 6, 2025, RBC Capital initiated coverage of Insulet (NasdaqGS:PODD) with a Outperform recommendation. Analyst Price Forecast Suggests 24.19% Upside As of March 3, 2025, the ...

Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target ...

Insulin device maker Insulet Corporation (NASDAQ:PODD) reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago. The ...

Investors interested in stocks from the Medical - Products sector have probably already heard of EssilorLuxottica Unsponsored ADR (ESLOY) and Insulet (PODD). But which of these two stocks offers value ...

Insulet Corporation's Omnipod 5 System received FDA clearance for type 2 diabetes in August. Insulet reported a 26% year-over-year revenue increase in Q2 2024, driven by strong demand for Omnipod 5.

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 78.5% compared with 7.3% growth of the industry during the same time frame. The S&P 500 ...